Passage BIO, Inc. PASG
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Passage BIO, Inc. (PASG) is a healthcare company listed in the US with a market value of about $14M.
Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -62%.
About Passage BIO
Passage BIO is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 14% over three years (dilution for shareholders).
Score: 0.0 / 5
Checks passed
- —
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$46M | -$65M | -$102M | -$136M | -$185M | -$112M | -$46M |
| Free cash flow | — | -$48M | — | — | — | — | — |
| EPS (diluted) | $-14.35 | $-21.04 | $-36.49 | $-49.05 | $-68.28 | $-57.10 | $-211.31 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -91.1% | -64.1% | -62.2% | -47.9% | -46.1% | -29.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Passage BIO pay a dividend?
Not currently.
Is Passage BIO a good stock to buy?
We do not give buy or sell advice. Passage BIO scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.